Black Rock Inc. Silverback Therapeutics, Inc. Transaction History

Black Rock Inc.

$4.35 Trillion
Q2 2024

A detailed history of Black Rock Inc. transactions in Silverback Therapeutics, Inc. stock. As of the latest transaction made, Black Rock Inc. holds 4,084,339 shares of SBTX stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares

4,084,339

Previous 2,658,239 53.65%

Holding current value

Previous $0 NaN%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	N/A	1,426,100 Added 53.65%	4,084,339 $0
Q1 2024 May 10, 2024	BUY	N/A	20,690 Added 0.78%	2,658,239 $0
Q4 2023 Feb 13, 2024	BUY	N/A	70,765 Added 2.76%	2,637,549 $0
Q3 2023 Nov 13, 2023	BUY	N/A	305,864 Added 13.53%	2,566,784 $0
Q2 2023 Aug 11, 2023	BUY	N/A	1,142,355 Added 102.13%	2,260,920 $0
Q1 2023 May 12, 2023	BUY	N/A	215,020 Added 23.8%	1,118,565 $0
Q4 2022 Feb 13, 2023	BUY	$0.0 - $6.07 $0 - $1.07 Million	175,841 Added 24.16%	903,545 $0
Q3 2022 Nov 14, 2022	BUY	$3.91 - $5.52 $77,648 - $109,621	19,859 Added 2.81%	727,704 $3.84 Million
Q2 2022 Aug 12, 2022	SELL	$2.9 - $4.44 $2.61 Million - $3.99 Million	-899,655 Reduced 55.97%	707,845 $3 Million
Q1 2022 May 12, 2022	BUY	$3.51 - $6.74 $99,027 - $190,155	28,213 Added 1.79%	1,607,500 $5.64 Million
Q4 2021 Feb 10, 2022	BUY	$6.03 - $11.67 $2.12 Million - $4.1 Million	351,626 Added 28.64%	1,579,287 $10.5 Million
Q3 2021 Nov 09, 2021	BUY	$9.98 - $35.22 $3.48 Million - $12.3 Million	348,296 Added 39.61%	1,227,661 $12.3 Million
Q2 2021 Aug 11, 2021	BUY	$24.71 - $44.28 $21.7 Million - $38.9 Million	879,365 New	879,365 $27.2 Million

Others Institutions Holding SBTX

# of Institutions

163

Shares Held

62.7M

Call Options Held

872K

Put Options Held

589K

View Full List

About Silverback Therapeutics, Inc.

Ticker SBTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,473,800
Description
Silverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverba...

More about SBTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

News

Stay updated on Black Rock Inc. with notifications on news.

Account